Evidence map›Paper›PMID 27602128›Full record

ArticleOncology letters2016

c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients.

Marco Johannes Battista, Marcus Schmidt, Sina Jakobi, Cristina Cotarelo, Katrin Almstedt, Anne-Sophie Heimes, Georgios-Marios Makris, Veronika Weyer, Antje Lebrecht, Gerald Hoffmann and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Marco Johannes BattistaDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Marcus SchmidtDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Sina JakobiDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Cristina CotareloDepartment of Pathology, University Medical Center Mainz, Mainz D-55131, Germany.
Katrin AlmstedtDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Anne-Sophie HeimesDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Georgios-Marios MakrisDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Veronika WeyerInstitute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz D-55131, Germany.
Antje LebrechtDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Gerald HoffmannDepartment of Gynecology and Obstetrics, University Medical Center Mainz, Mainz D-55131, Germany.
Michael EichbaumDepartment of Gynecology and Obstetrics, Marienkrankenhaus Frankfurt, Frankfurt D-60318, Germany.
Johannes Gutenberg University Mainz · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DEMarienkrankenhaus Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tyrosine kinase c-met alters signaling cascades such as the BRAF-MAPK and PI3K-PKB pathways. These alterations are involved in the carcinogenesis of type I but not type II ovarian cancer (OC). Therefore, the present study investigated the patterns of c-met expression in a cohort of consecutive patients with OC. c-met expression was determined by immunohistochemical analysis. Differences in c-met overexpression among subgroups of established clinicopathological features, including age, histological subtype, tumor stage, histological grading, post-operative tumor burden and completeness of chemotherapy, were determined by χ

Indexed as

c-metovarian cancerprognosistype II ovarian cancertype I ovarian cancer

Identifiers

PMID27602128
PMCPMC4998294
OpenAlexW2487425580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.